

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Zhaoke Ophthalmology Limited**  
**兆科眼科有限公司**

*(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)*  
**(Stock Code: 6622)**

**VOLUNTARY ANNOUNCEMENT – PATIENT ENROLLMENTS  
COMPLETE FOR ZKY001 OF PHASE II CLINICAL TRIAL FOR TPRK,  
PHASE II CLINICAL TRIAL FOR PTERYGIUM AND IIT FOR NK**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that patient enrollments were completed for three clinical trials of one of the Company’s core drug candidates, ZKY001.

The last patient was enrolled for Phase II clinical trial for transepithelial photorefractive keratectomy (“**TPRK**”, surgical treatment for myopia) on October 21, 2022. The trial involved 10 centers and enrolled a total of 120 patients.

The last patient was enrolled for Phase II clinical trial for Pterygium (growth in the cornea or in the conjunctiva) on October 31, 2022. The trial involved 10 centers and enrolled a total of 180 patients.

The last patient was enrolled for the investigator-initiated trial (“**IIT**”) for neurotrophic keratitis (“**NK**”) on October 31, 2022. The trial enrolled a total of 28 patients.

**ABOUT ZKY001**

ZKY001 is a seven-amino acid peptide derived from the functional fragment of Thymosin  $\beta$ 4 that binds actin, a type of protein that plays a central role in cell structure and movement. In addition to the Company’s leading Phase III innovative asset Cyclosporine A Ophthalmic Gel for dry eye, ZKY001 is another in-house developed program by the Company that is currently in clinical stage.

ZKY001 has broad applications in corneal wound healing and can potentially be used in multiple corneal repair indications. The Company is currently exploring four indications for ZKY001, including CED, corneal epithelial defect, TPRK, a surgical treatment for myopia, pterygium, a growth in the cornea or the conjunctiva, and NK, a rare degenerative corneal disease.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately develop and market ZKY001 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing with the shares of the Company.**

By order of the Board  
**Zhaoke Ophthalmology Limited**  
**Dr. Li Xiaoyi**  
*Chairman*

Hong Kong, November 8, 2022

*As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee, Ms. Tiantian Zhang, Ms. Cai Li and Mr. Chen Yu as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.*